LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
LivaNova PLC (LIVN) has announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting from December 6-10 in Los Angeles. The company will present multiple scientific posters featuring research on drug-resistant epilepsy treatments, including interim data from their CORE-VNS study.
The presentations will showcase research on VNS Therapy™ applications, including outcomes in children, genetic epilepsy patients, and Lennox-Gastaut Syndrome. Key topics include dosing and titration practices, long-term therapy outcomes, and healthcare services cost comparisons for Medicaid enrollees.
Poster presentations are scheduled for December 7-8, with author presentations from 12:00-2:00 PM PST. Additional displays will be available at the LivaNova Scientific Exhibit on December 9 from 8:00-11:00 AM PST.
LivaNova PLC (LIVN) ha annunciato la sua partecipazione all'Incontro Annuale della Società Americana per l'Epilessia (AES) 2024 che si terrà dal 6 al 10 dicembre a Los Angeles. L'azienda presenterà diversi poster scientifici che mostrano ricerche sui trattamenti per l'epilessia resistente ai farmaci, inclusi i dati interim del loro studio CORE-VNS.
Le presentazioni metteranno in evidenza ricerche sulle applicazioni della VNS Therapy™, comprese le risposte nei bambini, nei pazienti con epilessia genetica e nella sindrome di Lennox-Gastaut. I temi principali includono le pratiche di dosaggio e titolazione, gli esiti a lungo termine della terapia e i confronti dei costi dei servizi sanitari per i destinatari di Medicaid.
Le presentazioni dei poster sono programmate per il 7 e 8 dicembre, con presentazioni degli autori dalle 12:00 alle 14:00 PST. Ulteriori esposizioni saranno disponibili presso il LivaNova Scientific Exhibit il 9 dicembre dalle 8:00 alle 11:00 PST.
LivaNova PLC (LIVN) ha anunciado su participación en la Reunión Anual de la Sociedad Americana de Epilepsia (AES) 2024 del 6 al 10 de diciembre en Los Ángeles. La compañía presentará múltiples carteles científicos que muestran investigaciones sobre tratamientos para la epilepsia resistente a fármacos, incluyendo datos interinos de su estudio CORE-VNS.
Las presentaciones destacarán investigaciones sobre las aplicaciones de VNS Therapy™, incluidos los resultados en niños, pacientes con epilepsia genética y síndrome de Lennox-Gastaut. Los temas clave incluyen prácticas de dosificación y titulación, resultados de terapia a largo plazo y comparaciones de costos de servicios de salud para beneficiarios de Medicaid.
Las presentaciones de carteles están programadas para el 7 y 8 de diciembre, con presentaciones de autores de 12:00 a 14:00 PST. Exhibiciones adicionales estarán disponibles en el LivaNova Scientific Exhibit el 9 de diciembre de 8:00 a 11:00 PST.
LivaNova PLC (LIVN)가 미국 간질 학회(AES) 2024 연례 회의에 참여한다고 발표했습니다. 회의는 12월 6일부터 10일까지 로스앤젤레스에서 개최됩니다. 이 회사는 약물 저항성 간질 치료에 대한 연구를 다룬 다양한 과학 포스터를 발표할 예정이며, CORE-VNS 연구의 중간 데이터를 포함합니다.
발표는 어린이, 유전적 간질 환자 및 렌녹스-가스타 시냅스 증후군의 결과를 포함한 VNS Therapy™ 적용에 대한 연구를 보여줍니다. 주요 주제로는 투약 및 조정 방법, 장기 치료 결과, 그리고 메디케이드 가입자를 위한 의료 서비스 비용 비교가 있습니다.
포스터 발표는 12월 7일과 8일에 예정되어 있으며, 저자 발표는 오후 12시부터 2시까지 PST에 진행됩니다. 추가 전시물은 12월 9일 오전 8시부터 11시까지 LivaNova Scientific Exhibit에서 제공됩니다.
LivaNova PLC (LIVN) a annoncé sa participation à la Réunion Annuelle de la Société Américaine de l'Épilepsie (AES) 2024 qui se tiendra du 6 au 10 décembre à Los Angeles. L'entreprise présentera plusieurs affiches scientifiques mettant en avant des recherches sur les traitements de l'épilepsie résistante aux médicaments, y compris des données intermédiaires de leur étude CORE-VNS.
Les présentations mettront en lumière des recherches sur les applications de la VNS Therapy™, y compris les résultats chez les enfants, les patients atteints d'épilepsie génétique et le syndrome de Lennox-Gastaut. Les sujets clés incluent les pratiques de dosage et de titration, les résultats à long terme de la thérapie et les comparaisons de coûts des services de santé pour les bénéficiaires de Medicaid.
Les présentations des affiches sont prévues pour les 7 et 8 décembre, avec des présentations d'auteurs de 12h00 à 14h00 PST. Des expositions supplémentaires seront disponibles au LivaNova Scientific Exhibit le 9 décembre de 8h00 à 11h00 PST.
LivaNova PLC (LIVN) hat seine Teilnahme an der Jahrestagung der American Epilepsy Society (AES) 2024 vom 6. bis 10. Dezember in Los Angeles angekündigt. Das Unternehmen wird mehrere wissenschaftliche Poster präsentieren, die Forschung zu behandlungsresistenter Epilepsie zeigen, einschließlich Interimdaten aus ihrer CORE-VNS-Studie.
Die Präsentationen werden Forschungen zu den Anwendungen der VNS Therapy™ zeigen, einschließlich der Ergebnisse bei Kindern, Patienten mit genetischer Epilepsie und dem Lennox-Gastaut-Syndrom. Wichtige Themen sind Dosierungs- und Titrationspraktiken, langfristige Therapieergebnisse und Kostenvergleiche von Gesundheitsdienstleistungen für Medicaid-Berechtigte.
Die Posterpräsentationen sind für den 7. und 8. Dezember geplant, mit Autorenpräsentationen von 12:00 bis 14:00 Uhr PST. Weitere Ausstellungen sind am 9. Dezember von 8:00 bis 11:00 Uhr PST im LivaNova Scientific Exhibit verfügbar.
- None.
- None.
“Accelerating access to care and improving quality of life for epilepsy patients around the world are key priorities for LivaNova,” said Stephanie Bolton, President, Global Epilepsy at LivaNova. “These poster presentations, which share interim data from our CORE-VNS study as well as other clinical and health economic research, showcase our enduring commitment to advancing epilepsy research.”
The scientific poster presentations feature the research work of LivaNova employees and/or independent investigators. Conference attendees will have an opportunity to view posters during the 2024 AES Annual Meeting on Saturday, December 7 and Sunday, December 8, with presentations by authors from 12:00 – 2:00 p.m. PST each day. Posters will also be on display in the LivaNova Scientific Exhibit on Monday, December 9 from 8:00 – 11:00 a.m. PST.
Abstracts and poster times can be found at the American Epilepsy Society website.
Saturday, December 7
-
CORE-VNS: Dosing and Titration of VNS Therapy™ in Contemporary Clinical Practice (1.515) – Presented by Ryan Verner, PhD, LivaNova PLC,
Houston, Texas -
Long-Term Adjunctive VNS Therapy™ Use in Patients with Genetic Epilepsy – 24-Month CORE-VNS Outcomes (1.517) – Presented by Nicola Specchio, MD, PhD, FCCP,
Rome, Italy -
Long-term Experience of VNS Therapy™ in Children <18 Years of Age – 24-Month Outcomes from the CORE-VNS Study (1.516) – Presented by Muhammad Zafar, MD, FACNS,
Durham, North Carolina -
Focal Onset Seizure Response in Children 4-18 Years at 24 Months - Outcomes from the CORE-VNS Study (1.514) – James Wheless, MD,
Memphis, Tennessee -
Exploratory Analysis of an fMRI-Guided Titration Paradigm for Microburst VNS Therapy™ (1.513) – Presented by Ann Mertens, MD, Gent,
Belgium -
The Journey of Medicaid Enrollees with Drug-Resistant Epilepsy (DRE) to Neuromodulation (1.507) – Presented by Kathryn Evans, MPH,
Bethesda, Maryland -
Comparison of Healthcare Services and Costs Over the 2-Year Periods Immediately Before and After Vagus Nerve Stimulation (VNS Therapy™) Implantation Among Medicaid Enrollees with Drug-Resistant Epilepsy (DRE) (1.508) – Presented by Bronwyn Do Rego, MS, LivaNova PLC,
London, England -
Sleep Quality in Children with Confirmed Genetic Epilepsy Undergoing VNS Therapy™ (1.523) – Presented by Maxine Dibue, PhD, LivaNova PLC,
London, England
Sunday, December 8
-
Long-term Experience of VNS in Lennox-Gastaut Syndrome at 24 Months from the CORE-VNS Registry (2.249) – Presented by Paul D.
Lyons , MD, PhD,Winchester, Virginia -
Long-Term Outcomes in Patients with Generalized Tonic-Clonic Seizures Following VNS Therapy™: Interim CORE-VNS 36 Months (2.250) – Presented by Ana Suller-Marti, MD, PhD,
London, Ontario, Canada
About VNS Therapy™ for Epilepsy
VNS Therapy is clinically proven safe and effective as an add-on treatment for drug-resistant epilepsy in adults and children as young as 4 years old with partial onset seizures. VNS Therapy is designed to help reduce the frequency of seizures. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects approximately one in three people with epilepsy. For more information, visit VNSTherapy.com.
Incidence of adverse events following stimulation (>
INTENDED USE/INDICATIONS FOR USE–
The VNS Therapy™ System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events, clinical research, and the treatment of drug-resistant epilepsy with VNS Therapy™. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204503430/en/
LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com
Source: LivaNova PLC
FAQ
What will LivaNova (LIVN) present at the AES 2024 Annual Meeting?
When and where is the American Epilepsy Society 2024 Annual Meeting featuring LivaNova (LIVN)?
What are the key research areas for LivaNova's (LIVN) VNS Therapy presentations?
What is the CORE-VNS study that LivaNova (LIVN) will present data from?
